# CJC-1295 Ipamorelin Research: Mechanism, Synergy & Key Studies > CJC-1295 Ipamorelin research — the dual GHRH and ghrelin-receptor mechanism, the human synergy evidence, the DAC chemistry, and the single-component studies, each cited with DOI and PMID. Two receptors, one cell, a supra-additive pulse — and a careful note on what was studied as a blend (nothing) versus what was studied as components (a great deal). ## Start here The **CJC-1295 Ipamorelin research** comes down to a two-switch story. The pituitary gland makes growth hormone (GH), and two separate switches turn that release up. CJC-1295 flips the first switch — the GHRH receptor — and because of a feature called DAC it stays flipped for days. Ipamorelin flips the second switch — the ghrelin receptor — and produces a quick burst. Flip both and the gland releases more GH than either switch manages alone; that extra-large combined effect is called *supra-additive*, or synergy. This page walks through the receptor mechanism, the human evidence for the synergy, the chemistry that gives CJC-1295 its long life, and what each peptide showed on its own. One rule runs through all of it: every finding here is attributed to a study of a single component or to general synergy work, because the fixed blend itself has never been trialed. ## Cjc-1295 ipamorelin The term **cjc-1295 ipamorelin** names a research combination of two distinct molecules. CJC-1295 is a tetra-substituted analogue of the natural GHRH fragment hGRF(1-29); ipamorelin is a synthetic pentapeptide (a five-amino-acid chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2). CJC-1295 binds the GHRH receptor, a class-B G-protein-coupled receptor on the pituitary's GH-making cells (somatotrophs), raising the second messenger cAMP and driving GH synthesis and release. Ipamorelin binds GHS-R1a, the ghrelin receptor on the same cells, raising intracellular calcium through a different pathway. Two doors, one room — and that independence is the entire mechanistic basis for combining them [3] [4]. ## Ipamorelin cjc 1295 Stated as **ipamorelin cjc 1295**, the order of the names does not change the pharmacology, but it does foreground the secretagogue this monograph leads with. Ipamorelin's defining property is selectivity: it releases GH without raising ACTH or cortisol above GHRH-stimulated levels, even at more than 200 times the dose needed for half its GH effect, while matching the older GHRP-6's GH efficacy in swine [2]. Paired with the long-acting GHRH analogue CJC-1295, the intent is a clean, frequent GH pulse riding on a multi-day GHRH background. The pairing's logic is sound on paper; its real-world pulse profile remains uncharacterized in any controlled study. ## The dual-receptor mechanism and its synergy The synergy is documented in humans and explained in cells. In normal men, submaximal doses of a growth-hormone-releasing peptide (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms [3] — the foundational human evidence that a GHRP-plus-GHRH combination produces more GH than the sum of its parts. The receptor-level explanation followed: co-activating the cloned GHRH receptor and the ghrelin receptor in transfected cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, suggesting direct receptor cross-talk [4]. Mechanistically, the ghrelin arm also opposes somatostatin, the brake the body normally applies to GH — releasing that brake while pressing the GHRH accelerator is why the combined pulse is large. ## Cjc 1295 dac The **cjc 1295 dac** form is what gives this peptide its days-long action. CJC-1295 carries a C-terminal maleimidopropionamide-lysine — a Drug Affinity Complex, or DAC — that covalently bonds to Cys34 of serum albumin (a long-lived blood protein) after injection. In rats this bioconjugation produced about a four-fold increase in GH area-under-the-curve over two hours versus the unmodified GHRH fragment, with albumin-bound peptide still detectable in plasma beyond 72 hours [5]. In healthy adults, a single subcutaneous dose of CJC-1295 with DAC raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. The DAC is the single feature that separates the long-acting CJC-1295 from its short-acting, no-DAC cousin Mod GRF (1-29). ## Cjc ipamorelin Shortened to **cjc ipamorelin**, the combination's appeal is the union of a durable background and a clean spike. Beyond GH release, ipamorelin has shown effects worth recording. It dose-dependently increased longitudinal bone-growth rate in adult female rats (from roughly 42 to 52 µm/day over 15 days), an effect attributable to GH release [9], and it counteracted glucocorticoid-induced bone loss in rats, raising periosteal bone-formation rate four-fold versus glucocorticoid alone [11]. It also has a GH-independent action: in a rat model of post-surgical gut paralysis, repeated ipamorelin increased fecal output, food intake, and weight gain through the ghrelin receptor directly [10] — a reminder that the ghrelin arm does more than release GH. ## Cjc 1295 and ipamorelin Searched as **cjc 1295 and ipamorelin**, readers usually want to know what the pair does together — and the honest answer is that no controlled human trial has ever tested the pre-mixed combination. CJC-1295 with DAC reached Phase 2 before development was discontinued; ipamorelin was investigated (including a post-operative-ileus program) but never advanced to approval. The combination's case is therefore built entirely from each compound's separate literature [1] [2] [5] plus the general GHRH-plus-GHRP synergy evidence [3] [4]. This monograph states that limit plainly rather than papering over it: the components are well studied; the fixed blend is not. ## Pharmacokinetics and disposition The two halves keep different clocks, and the data is rodent-heavy. Ipamorelin's plasma clearance is roughly five-fold lower than GHRP-6's in rats, with 60 to 80% of a dose recovered in bile and urine [8]; its plasma presence is under about two hours in rodents, with a peak GH response near 40 minutes — and no validated human half-life has been published. CJC-1295 with DAC, by contrast, persists for days through albumin binding [5], while the no-DAC Mod GRF (1-29) is cleared in minutes-to-roughly-30-minutes through DPP-IV cleavage (an enzyme that snips native GHRH). Across the broader GH-secretagogue class, a safety review found the compounds generally well tolerated, with increased blood glucose from decreased insulin sensitivity the chief concern and long-term cancer and mortality data still needed [6]. ## Where the field is going Recent literature keeps these peptides in view as investigational tools rather than therapies. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance examined ipamorelin as a GH-axis secretagogue with preclinical metabolic and tissue-repair signals, while emphasizing the absence of rigorous human trials and the potential for serious harm. The ipamorelin scaffold has also proven chemically robust: it served as a backbone for boron-rich ghrelin-receptor-targeting conjugates that retained receptor activation [13], and as one of several secretagogue scaffolds tested for fluorine-18 PET imaging of the ghrelin receptor (the reported affinity values there belong to a different analogue, not to ipamorelin) [14]. Analytical work has likewise tracked glycine-modified ipamorelin analogues in seized doping material, underscoring that anti-doping panels must keep pace with modified secretagogues [12]. --- A printed-style monograph of the published CJC-1295 and ipamorelin record — every claim attributed to a single-component or synergy study, the fixed blend openly noted as never trialed; no clinic, no prescription, and nothing here dosed or dispensed.